Suppr超能文献

开欣散抑制 SAMP8 老年小鼠 Tau 病理和神经元凋亡。

Kai-Xin-San Inhibits Tau Pathology and Neuronal Apoptosis in Aged SAMP8 Mice.

机构信息

Health Sciences Institute, China Medical University, Shenyang, China.

Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China.

出版信息

Mol Neurobiol. 2022 May;59(5):3294-3309. doi: 10.1007/s12035-021-02626-0. Epub 2022 Mar 18.

Abstract

Alzheimer's disease (AD) is an age-related neurological disorder. Currently, there is no effective cure for AD due to its complexity in pathogenesis. In light of the complex pathogenesis of AD, the traditional Chinese medicine (TCM) formula Kai-Xin-San (KXS), which was used for amnesia treatment, has been proved to improve cognitive function in AD animal models. However, the active ingredients and the mechanism of KXS have not yet been clearly elucidated. In this study, network pharmacology analysis predicts that KXS yields 168 candidate compounds acting on 863 potential targets, 30 of which are associated with AD. Enrichment analysis revealed that the therapeutic mechanisms of KXS for AD are associated with the inhibition of Tau protein hyperphosphorylation, inflammation, and apoptosis. Therefore, we chose 7-month-old senescence-accelerated mouse prone 8 (SAMP8) mice as AD mouse model, which harbors the behavioral and pathological hallmarks of AD. Subsequently, the potential underlying action mechanisms of KXS on AD predicted by the network pharmacology analyses were experimentally validated in SAMP8 mice after intragastric administration of KXS for 3 months. We observed that KXS upregulated AKT phosphorylation, suppressed GSK3β and CDK5 activation, and inhibited the TLR4/MyD88/NF-κB signaling pathway to attenuate Tau hyperphosphorylation and neuroinflammation, thus suppressing neuronal apoptosis and improving the cognitive impairment of aged SAMP8 mice. Taken together, our findings reveal a multi-component and multi-target therapeutic mechanism of KXS for attenuating the progression of AD, contributing to the future development of TCM modernization, including KXS, and broader clinical application.

摘要

阿尔茨海默病(AD)是一种与年龄相关的神经退行性疾病。目前,由于其发病机制复杂,尚无有效的 AD 治疗方法。鉴于 AD 发病机制复杂,用于治疗健忘症的中药方剂开心散(KXS)已被证明可改善 AD 动物模型的认知功能。然而,KXS 的活性成分和作用机制尚未阐明。在这项研究中,网络药理学分析预测 KXS 产生 168 种候选化合物,作用于 863 个潜在靶点,其中 30 个与 AD 相关。富集分析表明,KXS 治疗 AD 的机制与抑制 Tau 蛋白过度磷酸化、炎症和细胞凋亡有关。因此,我们选择 7 月龄快速老化小鼠品系 8(SAMP8)作为 AD 小鼠模型,该模型具有 AD 的行为和病理特征。随后,通过网络药理学分析预测 KXS 对 AD 的潜在作用机制,并在 SAMP8 小鼠经灌胃给予 KXS 3 个月后进行实验验证。我们观察到 KXS 上调 AKT 磷酸化,抑制 GSK3β 和 CDK5 激活,并抑制 TLR4/MyD88/NF-κB 信号通路,从而减轻 Tau 过度磷酸化和神经炎症,抑制神经元凋亡,改善老年 SAMP8 小鼠的认知障碍。总之,我们的研究结果揭示了 KXS 缓解 AD 进展的多成分、多靶点治疗机制,为包括 KXS 在内的中药现代化和更广泛的临床应用奠定了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee47/9016055/754014ac701c/12035_2021_2626_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验